Obesity is one of the most widespread diseases of the 21st century and comes with a high risk of cardiovascular disease, type 2 diabetes, cancer and many others. Treating obese patients with drugs was not very effective so far, often with unwanted side effects.

EraCal closes this gap by developing potent and highly selective appetite suppressants. Animal models showed superior effectiveness at reducing weight over current drugs on the market. EraCal was spun out of the University of Zurich and Harvard University in 2018.